Volume 2.05 | Feb 11

     In this issue: Science News | Current Publications | Industry News | Policy News | Events
 
TOP STORY
Sweeping View of Prostate Cancer Genome Yields Deep Insights
For the first time, researchers have laid bare the full genetic blueprint of multiple prostate tumors, uncovering alterations that have never before been detected and offering a deep view of the genetic missteps that underlie the disease. [Press release from Weill Cornell Medical College discussing online prepublication in Nature]

ON134_645x110.jpg
SPECIAL FEATURE

social_default_facebook_icon.jpg Cell Therapy News is now on Facebook. Join us!

social_default_twitter_icon.jpg Follow us on Twitter! @ProstateCell

Interested in recruiting talented individuals? Post your career opportunities in Prostate Cell News at no cost. Contact us at [email protected]

SCIENCE NEWS
Gene Test Could Solve Prostate Cancer Riddle and Spare Thousands from Surgery
A genetic pattern could predict how aggressive prostate cancer is before treatment, and whether the disease will come back in men who have already been treated, according to research. [Press release from the Queen Mary University of London discussing online prepublication in The Lancet Oncology]

ON137_SocialMedia_645x110
CURRENT PUBLICATIONS (Ranked by Impact Factor of the Journal)

LABORATORY RESEARCH

The Genomic Complexity of Primary Human Prostate Cancer
Here scientists present the complete sequence of seven primary human prostate cancers and their paired normal counterparts. [Nature]

Cancer Genetics-Guided Discovery of Serum Biomarker Signatures for Diagnosis and Prognosis of Prostate Cancer
Here researchers describe a two-stage strategy for the discovery of serum biomarker signatures corresponding to specific cancer-causing mutations and its application to prostate cancer in the context of the commonly occurring phosphatase and tensin homolog tumor-suppressor gene inactivation. [Proc Natl Acad Sci USA]

Altered TGF-Beta Signaling in a Subpopulation of Human Stromal Cells Promotes Prostatic Carcinogenesis
To determine the mechanisms by which stromal heterogeneity because of loss of transforming growth factor-beta (TGF-beta) receptor II might contribute to cancer progression, investigators attenuated TGF-beta signaling in a subpopulation of immortalized human prostate fibroblasts in a model of tumor progression. [Cancer Res]

Homeodomain Protein DLX4 Counteracts Key Transcriptional Control Mechanisms of the TGF-Beta Cytostatic Program and Blocks the Antiproliferative Effect of TGF-Beta
Researchers demonstrate that DLX4 blocks the antiproliferative effect of transforming growth factor-beta (TGF-beta). [Oncogene]

Systematic Biochemical Analysis of Somatic Missense Mutations in DNA Polymerase Beta Found in Prostate Cancer Reveal Alteration of Enzymatic Function
Investigators have previously identified 20 somatic pol beta mutations in prostate tumors, many of them missense. In the current paper they describe the effect of all of these somatic missense pol beta mutations (p.K27N, p.E123K, p.E232K, p.P242R, p.E216K, p.M236L, and the triple mutant p.P261L/ T292A/ I298T) on the biochemical properties of the polymerase in vitro, following bacterial expression and purification of the respective enzymatic variants. [Hum Mutat]

Low Dose Valproic Acid Enhances Radiosensitivity of Prostate Cancer through Acetylated p53-Dependent Modulation of Mitochondrial Membrane Potential and Apoptosis
In this study, scientists demonstrate in prostate cancer cells that Valproic acid at low concentrations has minimal cytotoxic effects, yet can significantly increase radiation induced apoptosis. [Mol Cancer Res]

ERG Oncogene Modulates Prostaglandin Signaling in Prostate Cancer Cells
This study suggests that ETS related gene (ERG) activation plays a role in prostaglandin signaling because knockdown of ERG expression in TMPRSS2-ERG fusion containing prostate cancer cells leads to altered levels of the 15-hydroxy-prostaglandin dehydrogenase, a tumor suppressor and prostaglandin catabolizing enzyme, and prostaglandin E2. [Cancer Biol Ther]

Effects of Nobiletin on PhIP-Induced Prostate and Colon Carcinogenesis in F344 Rats
The current study was designed to investigate the effects of nobiletin (5,6,7,8,3′,4′-hexamethoxy flavone) on 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP) – induced prostate and colon carcinogenesis. [Nutr Cancer]

CLINICAL RESEARCH

Prognostic Value of an RNA Expression Signature Derived from Cell Cycle Proliferation Genes in Patients with Prostate Cancer: A Retrospective Study
The results of this study provide strong evidence that the cell cycle progression score is a robust prognostic marker, which, after additional validation, could have an essential role in determining the appropriate treatment for patients with prostate cancer. [Lancet Oncol]

Activation of the Androgen Receptor by Intratumoral Bioconversion of Androstanediol to Dihydrotestosterone in Prostate Cancer
In this report, researchers demonstrate the extent of androgen receptor transactivation in the presence of 5alpha-androstane-3alpha,17beta-diol (androstanediol) in prostate-derived cell lines parallels the bioconversion of androstanediol to dihydrotestosterone. [Cancer Res]

Intact and Internally Cleaved Free Prostate-Specific Antigen in Patients With Prostate Cancer With Different Pathologic Stages and Grades
The objective of this study is to measure the concentration levels of free prostate-specific antigen isoforms in patients with prostate cancer selected for curative treatment using radical prostatectomy and to study the association between the isoforms and the pathologic cancer stage and grade. [Urology]

INDUSTRY NEWS
Mount Sinai Comprehensive Cancer Center – First Site in South Florida to Provide New Prostate Cancer Treatment
The Mount Sinai Comprehensive Cancer Center in Miami Beach, Florida is one of only 50 sites throughout the country and, currently, the only site in South Florida to treat advanced prostate cancer patients with a new cellular immunotherapy treatment called PROVENGE®, the first in a new therapeutic class known as autologous cellular immunotherapies. [PR Newswire Press Release]

AstraZeneca Halts Phase III Trial of ZIBOTENTAN in Non-Metastatic Castrate Resistant Prostate Cancer
AstraZeneca announced that the Phase III ENTHUSE Study 15, studying zibotentan monotherapy in patients with non-metastatic castrate resistant prostate cancer, will be stopped following the results of an early efficacy review by the Independent Data Monitoring Committee. [AstraZeneca Press Release]

Harbor BioSciences Wraps Up Phase I/IIa Prostate Cancer Study
Harbor BioSciences, Inc. announced it is closing the clinical sites of its U.S.-based Phase I/IIa clinical trial with Apoptone® (HE3235) for castration resistant prostate cancer – also referred to as hormone resistant prostate cancer. [Harbor BioSciences Press Release]

Genomic Health Announces Year-End 2010 Financial Results, Provides 2011 Financial Outlook
Genomic Health, Inc. reported financial results and business progress for the quarter ended December 31, 2010. [Genomic Health, Inc. Press Release]
POLICY NEWS

National Institutes of Health (United States

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)

EVENTS
NEW American Association for Cancer Research-National Cancer Institute (AACR-NCI) Conference on Systems Biology: Confronting the Complexity of Cancer
February 27 – March 2, 2011
La Jolla, United States

NEW Prostate of the Art
March 3, 2011
Toronto, Canada

Visit our events page to see a complete list of events in the prostate cell community.
JOB OPPORTUNITIES
Lab Technologist – Human Embryonic and Induced Pluripotent Stem Cells (STEMCELL Technologies)

Lab Technologist – Tissue Culture (STEMCELL Technologies)

Assistant Professor (University of Pittsburgh School of Medicine, Center for Cellular and Molecular Engineering)

Process Technical Development Scientist (StemCells, Inc.)

Field Applications Specialist – Cell Therapy (Medical) (Pall Corporation)

Postdoctoral Position – Germline Stem Cells (R. L. Brinster, School of Veterinary Medicine, University of Pennsylvania)

Post-doctoral Position (University of Houston-Center for Nuclear Receptors and Cell Signaling)

Post-doctoral Positions (University of Texas MD Anderson Cancer Center)

Cell Processing Associates (Kelly Scientific Resources)

Scientific Officer (The Institute of Cancer Research)

Recruit Top Talent
Reach more than 11,000 potential candidates by posting your organization’s career opportunities with the Connexon Creative Job Board at no cost.
Visit here to post your career opportunities.

Have we missed an important article or publication in Prostate Cell News? Click here to submit!

Comments or Suggestions? Email [email protected] with your feedback.

Learn more about Prostate Cell News: Archives | Events | Contact Us